Executives Outline Expansion Plans at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies provided the latest major news from their companies across the bio/pharmaceutical manufacturing value chain at the DCAT Member Company Forum at DCAT Week 2022.

CEOs and senior executives from DCAT Member Companies provided the latest major news from their companies across the bio/pharmaceutical manufacturing value chain at the DCAT Member Company Forum at DCAT Week 2022.

Global expansions highlighted
This year’s DCAT Member Company Announcement Forum, which was held on March 21, 2022, kicked off DCAT Week 2022 with CEOs and senior executives highlighting major news announcements from their companies with developments across the global bio/pharmaceutical manufacturing value chain. DCAT Week, held March 21–24, 2022, is the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT) and the premier industry event for companies engaged in bio/pharmaceutical development and manufacturing.

Expansions in biomanufacturing (drug substance), both traditional biologics and new modalities, such as cell and gene therapies, including select investments in mRNA manufacturing, were a major area of focus of several companies’ announcements, with certain companies highlighting billion-dollar plus expansion plans.

So which companies are making the news in biomanufacturing? On the CDMO side, Thermo Fisher Scientific, Samsung Biologics, Lonza, Catalent, AGC Biologics, and IDT Biologika are moving forward with key expansions in biologics, as is Cytiva, the former Biopharma business of GE Life Sciences, now part of Danaher Corporation, and a large supplier of products supporting bioprocessing.

Several of these CDMOs with integrated capabilities in biologic drug substance and drug-product manufacturing also provided updates on their expansions in fill–finish/sterile drug-product development and manufacturing (Thermo Fisher Scientific, Lonza, Catalent, and IDT Biologika) as did Selkirk Pharma, a CDMO of injectable products.

Also on the drug-product side, Catalent highlighted the integration of its $1-billion acquisition of Bettera, providing it with innovative dose technologies for consumer healthcare products.  CordenPharma outlined the acquisition of three drug-product manufacturing facilities to expand its capacity for oral dosage forms and other dosage forms (sachets, non-sterile liquids).

On the small-molecule drug substance side, several companies announced expansions. WuXi STA is proceeding with a major expansion plan in its global R&D and manufacturing network for small-molecule APIs, including high-potency APIs, as well as for oligonucleotides, peptides, and their conjugates in addition to investments in flow chemistry and biocatalysis. HAS Healthcare Advanced Healthcare Systems (formerly Helsinn Advanced Synthesis) is progressing a multi-year expansion plan, and Cambrex announced a $100-million expansion in small-molecule API development and manufacturing.

Details of all these announcements, including investment amounts, capacity additions, and timelines for completion/start-up are outlined in the new stories below.  Plus, other DCAT Member Companies are making the news: watch for the upcoming April 8th issue of DCAT Value Chain Insights for highlights.

Recent Feature Articles

The CDMO/CMO Report: Strong Growth Drives Contract ADC Market

Double-digit growth is projected for the contract market for antibody drug conjugates (ADCs). Increased investment by both large bio/pharma companies and smaller ADC innovators is fueling demand for for high-potency manufacturing and conjugation services. Which companies lead the charge?

In Case You Missed It: AI Front and Center for Supply Chain Management 

How will artificial intelligence (AI) shape sourcing and supply chain management? A newly released study by DCAT and a panel discussion at DCAT Week examined AI’s potential, the types of projects and activities for which AI may be applied, and its challenges to its use and adoption.

Big Pharma’s Manufacturing Muscle: What Major Expansions Are Underway?

Multi-billion dollar investments by Novo Nordisk and Eli Lilly and Company to increase manufacturing capacity for their GLP-1 drugs represent the largest capital expansions by the large bio/biopharma companies. What…

Euroapi, Sanofi’s Spinout CDMO Details Restructuring Plan, Including Mfg

When launched in 2022, Euroapi, the spinout API and CDMO business of Sanofi, now a stand-alone entity, had ambitions to be the leader in small-molecule APIs and number two in the global API market. This week, the company detailed a restructuring plan. What is its plan going forward?